CLDI.US Calidi Biotherapeutics Inc.

Healthcare Biotechnology USA Stocks
0.6219 USD
Close of Nov 13, 2026
0.6200 24.80
Market cap
USD 2.29M
P/E
-
P/B
0.54x
ROE
-974.0%
Dividend yield
248.12%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CLDI.US undervalued?

Graham number

The Graham number of Calidi Biotherapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Calidi Biotherapeutics Inc. fundamental analysis

No fundamental analysis for Calidi Biotherapeutics Inc. yet.

Calidi Biotherapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Calidi Biotherapeutics Inc.

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metast…

Full company profile